ライフサイエンスコーパス: standard medical therapy

1 scularization have refractory angina despite standard medical therapy.

2 rable quality of life compared to exhaustive standard medical therapy.

3 A, n = 23) or placebo (group B, n = 24) plus standard medical therapy.

4 itis (UC) was cost-effective compared to the standard medical therapy.

5 considerable morbidity and mortality despite standard medical therapy.

6 cranial hypertension that is unresponsive to standard medical therapy.

7 who have increased ICP that is resistant to standard medical therapy.

8 of symptomatic gastroparesis unresponsive to standard medical therapy.

9 ents with congestive heart failure receiving standard medical therapy.

10 two groups on the basis of their response to standard medical therapy.

11 or patients with gastroparesis refractory to standard medical therapy.

12 lating system therapy and patients receiving standard medical therapy.

13 l health care strategies in conjunction with standard medical therapies.

14 ndividuals, even after revascularisation and standard medical therapies.

15 atients were treated either with one or more standard medical therapies (72 patients) or with osteopa

16 ch use was not associated with choices about standard medical therapies after we controlled for clini

17 dard medical therapy (intervention group) or standard medical therapy alone (control group).

18 ntervention compared with those who received standard medical therapy alone in both per-protocol (28

19 scular therapy compared with those receiving standard medical therapy alone.

20 s in addition to standard medical therapy or standard medical therapy alone.

21 tic valve implantation (TAVI) is superior to standard medical therapy and noninferior to surgical aor

22 ase (N-ERD) can be difficult to control with standard medical therapy and sinus surgery.

23 All patients also received standard medical therapy and were followed for 12 months

24 9 patients were randomly assigned to receive standard medical therapy, and 229 to receive standard me

25 e benefits from medications added to current standard medical therapy, and the harms of screening and

26 We conclude that standard medical therapies are ethically justified and t

27 ies are being explored for IIH refractory to standard medical therapy, but their efficacy and safety

28 ent with either endovascular thrombectomy or standard medical therapy, by CTP as relative cerebral bl

29 my (predominantly using stent retrievers) or standard medical therapy (control) between June 1, 2010,

30 orbent recirculating system treatment versus standard medical therapy (control).

31 upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out

32 The addition of colchicine to standard medical therapy did not significantly affect ca

33 h severe, class IV heart failure who receive standard medical therapy exhibit a 1-year mortality rate

34 nt benefit of endovascular thrombectomy over standard medical therapy for improved functional outcome

35 The standard medical therapy for symptomatic benign prostati

36 Adding an ACE inhibitor to standard medical therapy improves outcomes, including re

37 We sought to examine the use and impact of standard medical therapies in patients with end-stage re

38 UCS and AMT, as an adjuvant to standard medical therapy in acute chemical injury, are e

39 Trial of Intensified versus standard Medical therapy in Elderly patients with Conges

40 ), the TIME-CHF (Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Conges

41 of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart fa

42 (predominantly using stent retrievers) with standard medical therapy in patients with anterior circu

43 with lower in-hospital mortality rates than standard medical therapy in this Registry.

44 We first review standard medical therapies, including gonadotropin-relea

45 itored closely and treated aggressively with standard medical therapy, including diuretics, if they d

46 examined whether the addition of E. coli to standard medical therapy increased the chance of remissi

47 assigned (1:1) to endovascular therapy plus standard medical therapy (intervention group) or standar

48 Standard medical therapy is highlighted and more recent

49 ed by abnormal muscle contractions for which standard medical therapy is often inadequate.

50 randomized to either thoracentesis (n=68) or standard medical therapy (n=67).

51 igtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alo

52 were randomly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS in

53 s superior in improving symptoms compared to standard medical therapy (otilonium bromide, OB).

54 standard medical therapy, and 229 to receive standard medical therapy plus a single-chamber ICD.

55 ial, 57 patients with SSc-PAH on stable-dose standard medical therapy received two infusions of 1,000

56 tonia that is not adequately controlled with standard medical therapy should be referred for consider

57 ed to groups given a combination of FPSA and standard medical therapy (SMT) (FPSA group, n = 77) or o

58 Patients were randomized to ECAD and standard medical therapy (SMT) or SMT alone.

59 sing single LDL apheresis and statins versus standard medical therapy (SMT) with no LDL apheresis and

60 Patients were randomized to receive standard medical therapy (STD) or STD plus an ICD.

61 ng early colectomy with IPAA strategy to the standard medical therapy strategy.

62 Our study demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs

63 isease-specific management clinics join more standard medical therapies such as angiotensin convertin

64 All patients also received standard medical therapy together with a 1-week course o

65 ressive infectious keratitis unresponsive to standard medical therapy underwent RB-PDAT at the Bascom

66 adjusted life-years gained (QALY-gained) for standard medical therapy was 20.78, while QALY-gained fo

67 ion for acute decompensated HF refractory to standard medical therapy was associated with high incide

68 ients with stable coronary disease receiving standard medical therapy, we evaluated the pharmacokinet

69 compensated heart failure who were receiving standard medical therapy were randomly assigned to an ex

70 d had increased ICP that was unresponsive to standard medical therapy were studied.

71 uals with infectious keratitis refractory to standard medical therapy who underwent RB-PDAT at the Ba

72 entricular ejection fraction <36% to receive standard medical therapy with or without an ICD.

73 ospital to immediate transfer for PCI, or to standard medical therapy with transfer for rescue angiop